Cargando…
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
AIMS: The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of secukinumab with different devices for subcutaneous (s.c.) administration of 2 mL. METHODS: A phase 1 study in healthy subjects with 6 devices to administer 2 mL injection volumes was conducted to evaluat...
Autores principales: | Bruin, Gerard, Hockey, Hans‐Ulrich P., La Stella, Phillip, Sigurgeirsson, Bárdur, Fu, Rong, Patekar, Manmath, Charef, Pascal, Woessner, Ralph, Boutouyrie‐Dumont, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015744/ https://www.ncbi.nlm.nih.gov/pubmed/31658377 http://dx.doi.org/10.1111/bcp.14155 |
Ejemplares similares
-
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2019) -
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System
por: Ji, Yan, et al.
Publicado: (2023) -
Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021) -
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017) -
Association of Secukinumab Treatment With Tuberculosis Reactivation in
Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)